Mirum Pharmaceuticals, Inc. (MIRM) stock
Close on Nov 12, 2026Market cap $6.06BP/E –Yield –
Mirum Pharmaceuticals, Inc. grew revenue 44.0% to $618.07M over the twelve months to Jun 30, 2026. Free cash flow was -$228.74M, down 2751.5% from a year earlier. At the latest close the market valued the company at $6.06B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $6.06B
- P/E ratio
- –
- Price to sales
- 9.80
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -3.77%
Fundamentals
- Revenue
- $618.07M
- Net income
- -$860.21M
- EPS, diluted
- -$14.55
- Free cash flow
- -$228.74M
- Book value per share
- -$0.16
- Diluted shares
- 63M
Trading
- Next earnings
- Feb 24, 2027 (estimated, after the close)
- Previous close
- $94.61
- Open
- $93.54
- Day's range
- $92.13 – $95.06
- Volume
- 392,856
- Average volume (20 days)
- 616,358
- Index membership
- Russell 2000, Russell 3000 (since Feb 2020)
- Beta (5 years)
- 0.63
- 52-week range
- $63.23 – $130.00
- RSI (14 days)
- 58.8
- Volatility (1 year)
- 48.6%
- Relative volume
- 0.56×
- WACC
- 8.0%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | MIRM | S&P 500 | Difference | MIRM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +8.4% | -2.7% | +11.1 pts | ||
| 3 months | -5.7% | -1.7% | −4.0 pts | ||
| Year to date | +18.2% | +11.9% | +6.3 pts | ||
| 1 year | +31.9% | +12.0% | +19.9 pts | ||
| 3 years | +226.2% | +78.2% | +148.0 pts | +48.3% | +21.2% |
| 5 years | +487.7% | +73.2% | +414.5 pts | +42.5% | +11.6% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Mirum Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- News
- Results
- Results
About Mirum Pharmaceuticals
Pharmaceutical Preparations
This biopharmaceutical company specializes in developing and commercializing therapeutic treatments for rare and orphan diseases with significant unmet medical needs. Its commercial portfolio features three approved prescription medicines: Livmarli, an ileal bile acid transporter inhibitor indicated for cholestatic pruritus in Alagille syndrome and progressive familial intrahepatic cholestasis; Cholbam, formulated for pediatric and adult patients with bile acid synthesis and peroxisomal disorders; and Ctexli, an approved therapy for cerebrotendinous xanthomatosis. The firm also maintains an active clinical pipeline pursuing expanded indications and investigating product candidates for cholestatic liver conditions, chronic viral infections, and neurocognitive disorders. Its therapies primarily serve specialized patient groups managed through medical providers and dedicated healthcare channels.
Company profile, executives and historyMirum Pharmaceuticals stock: common questions
What is Mirum Pharmaceuticals's stock price?
MIRM closed at $93.33 on Nov 12, 2026, down 1.35% on the day. Over the past 52 weeks it traded between $63.23 and $130.00.
What is Mirum Pharmaceuticals's market cap?
Mirum Pharmaceuticals was worth $6.06B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is MIRM's P/E ratio?
Mirum Pharmaceuticals lost money over the twelve months to Jun 30, 2026 (diluted EPS -$14.55), so it has no meaningful P/E ratio.
How much revenue does Mirum Pharmaceuticals make?
Mirum Pharmaceuticals reported revenue of $618.07M for the twelve months to Jun 30, 2026, up 44.0% from a year earlier.
Does Mirum Pharmaceuticals pay a dividend?
No. Mirum Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Mirum Pharmaceuticals report earnings next?
Mirum Pharmaceuticals is expected to report Q4 FY2026 results on Feb 24, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has MIRM stock performed over the past year?
Including dividends, MIRM returned +31.9% over the past year, against +12.0% for the S&P 500.
How many MIRM shares are sold short?
7M shares were sold short at the latest FINRA report, 11.07% of the float, or 11.8 days of average trading volume.
Who are Mirum Pharmaceuticals's competitors?
Companies most similar to Mirum Pharmaceuticals by business, industry and size include TVTX, RARE, PTCT, BBIO, ARWR.
See a number that looks wrong?